Grape King BioTPE:1707 -0.11%78 PB Ratio is 1.30 as of Jul. 09, 2026, which is 54% below its 10-year median of 2.83. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Grape King Bio ranks better than 65.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-09), Grape King Bio's share price is NT$91.00. Grape King Bio's Book Value per Share for the quarter that ended in Dec. 2025 was NT$69.81. Hence, Grape King Bio's PB Ratio of today is 1.30.
Good Sign:
Grape King Bio Ltd stock PB Ratio (=1.33) is close to 10-year low of 1.33.
The historical rank and industry rank for Grape King Bio's PB Ratio or its related term are showing as below:
TPE:1707'
s PB Ratio Range Over the Past 10 Years
Min: 1.3 Med: 2.83 Max: 10.23
Current: 1.3
During the past 13 years, Grape King Bio's highest PB Ratio was 10.23. The lowest was 1.30. And the median was 2.83.
TPE:1707's PB Ratio is ranked better than 65.94% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs TPE:1707: 1.30
During the past 12 months, Grape King Bio's average Book Value Per Share Growth Rate was 2.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Grape King Bio was 18.70% per year. The lowest was 2.60% per year. And the median was 10.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Grape King Bio PB Ratio Related Terms
Grape King Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Grape King Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Grape King Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Grape King Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Grape King Bio (TPE:1707) has a PB Ratio of 1.30 as of Jul. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grape King Bio and its competitors. This is 54% below median its historical median of 2.83. Over the past decade, Grape King Bio's PB Ratio has ranged from 1.30 to 10.23. According to the industry distribution chart, Grape King Bio ranks #313 out of 919 companies in the Drug Manufacturers industry, placing it in the top 34.1%.
Is Grape King Bio's PB Ratio too high?
Grape King Bio's current PB Ratio of 1.30 is 54% below median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 10.23. The Drug Manufacturers industry median PB Ratio is 1.91. Grape King Bio's value of 1.30 is 31.9% below this industry median. Based on the distribution chart, Grape King Bio ranks #313 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #313 out of 919 companies for PB Ratio. This puts Grape King Bio in the upper half of its industry. The industry median PB Ratio is 1.91. Grape King Bio's value of 1.30 is 31.9% below this benchmark. Historically, Grape King Bio's own PB Ratio has ranged from 1.30 to 10.23 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 1.91, Grape King Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current PB Ratio of 1.30 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current PB Ratio is 1.30, which is 54% below median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current PB Ratio is 1.30, which is 54% below median its 10-year median of 2.83 and 31.9% below the Drug Manufacturers industry median of 1.91. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current PB Ratio is 1.30 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
PB Ratio: 1.30 (54% below median its 10-year median of 2.83)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 31.9% below the Drug Manufacturers median (#313 of 919)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
